NAS
RYTM icon

Nykredit A/S’s Rhythm Pharmaceuticals RYTM Stock Holding History

Nykredit A/S’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Buy
+2,525
New +$228K ﹤0.01% 902

Other funds holding RYTM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Nykredit A/S's RYTM Position: Q2 2026 in Review

Nykredit A/S opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 2,525 shares worth $280K. The stake represents ﹤0.01% of the portfolio and ranks #902 among its holdings.

200 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Nykredit A/S held 2,525 shares of Rhythm Pharmaceuticals worth $280K as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #902 holding.
  • 200 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.